In Canada, the forecast for antidepressant medicine sales shows a steady growth trajectory from 2024 to 2028. Sales are poised to increase from 1.78 billion CAD in 2024 to 1.95 billion CAD in 2028. The year-on-year growth rates show a consistent increase in market value, reflecting a growing demand. Comparatively, the 2023 figure, at 1.72 billion CAD, indicates a continued upward trend with a notable compounded annual growth rate (CAGR) over the five-year period up to 2028.
Future trends to watch for include potential impacts of new pharmaceutical regulations, advancements in mental health treatments, and increased public awareness and reducing stigma around mental health, all of which could influence market dynamics and sales volumes.
